Back Back
Cell No. : Cell Name
RCB0035 : WEHI-3  update : 2022/02/28
CommentMouse cell line derived from leukemia. Secretes cytokines for hematopoietic cells.
Comment from the depositor
Terms and conditionsThere is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (
Basic information Depositor Kanazawa, Satoshi
Year of deposit 1987
Another name W3(H)
Animal mouse < Mammals
Strain name BALB/c
Tissue blood
Disease name leukemia
Classification other
History Hirosima Univ.- Yanagihara
Lifespan infinite
Morphology lymphocyte-like
Cellosaurus(Expasy) CVCL_3622
deposit info
lot info
Medium Medium List
Culture type Suspension cells
Medium and additives RPMI1640 + 10% FBS
Antibiotics Free
Passage method dilution
Culture information Passage ratio 1 : 10 split
SC frequency Subculture : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
SSLP(mouse) OK
Isozyme LD, NP
deposit info
lot info
Reference information Reference 6
User's Publication 20

To topTop
5287  McKean DJ, Infante AJ, Nilson A, Kimoto M, Fathman CG, Walker E, Warner N.  Major histocompatibility complex-restricted antigen presentation to antigen-reactive T cells by B lymphocyte tumor cells.  J Exp Med  1981  154(5):1419-31  PubMed ID: 6170720
980  Metcalf D  Clonal extinction of myelomonocytic leukemic cells by serum from mice injected with endotoxin.  Int J Cancer  1980  25:225-33  PubMed ID: 6967053
1294  Ralph P, Nakoinz I  Direct toxic effects of immunopotentiators on monocytic, myelomonocytic, and histiocytic or macrophage tumor cells in culture.  Cancer Res  1977  37:546-50  PubMed ID: 318922
716  Ralph P, Nakoinz I  Antibody-dependent killing of erythrocyte and tumor targets by macrophage-related cell lines: enhancement by PPD and LPS.  J Immunol  1977  119:950-54  PubMed ID: 894031
1141  Ralph P, Moore, M A, Nilsson K  Lysozyme synthesis by established human and murine histiocytic lymphoma cell lines.  J Exp Med  1976  143:1528-33  PubMed ID: 1083890
5289  Metcalf D, Moore MA, Warner NL.  Colony formation in vitro by myelomonocytic leukemic cells.  J Natl Cancer Inst  1969  43(4):983-1001  PubMed ID: 5259326

To topTop
User's Publication
16770  Fujino T, Suda K, Koga T, Hamada A, Ohara S, Chiba M, Shimoji M, Takemoto T, Soh J, Mitsudomi T.  Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation  J Hematol Oncol  2022  15(1):79  PubMed ID: 35690785
11561  Yamada R, Fukumoto R, Noyama C, Fujisawa A, Oka S, Imamura T.  An epidermis-permeable dipeptide is a potential cosmetic ingredient with partial agonist/antagonist activity toward fibroblast growth factor receptors.  J Cosmet Dermatol  2020  19(2):477-484  PubMed ID: 31099492
11622  Fujino T, Kobayashi Y, Suda K, Koga T, Nishino M, Ohara S, Chiba M, Shimoji M, Tomizawa K, Takemoto T, Mitsudomi T.  Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro.  J Thorac Oncol  2019  14(10):1753-1765  PubMed ID: 31279006
17202  Elbadry MI, Mizumaki H, Hosokawa K, Espinoza JL, Nakagawa N, Chonabayashi K, Yoshida Y, Katagiri T, Hosomichi K, Zaimoku Y, Imi T, Nguyen MAT, Fujii Y, Tajima A, Ogawa S, Takenaka K, Akashi K, Nakao S.  Escape hematopoiesis by HLA-B5401-lacking hematopoietic stem progenitor cells in men with acquired aplastic anemia  Haematologica  2019  104(10):e447-e450  PubMed ID: 30890597
11331  Nishino M, Suda K, Kobayashi Y, Ohara S, Fujino T, Koga T, Chiba M, Shimoji M, Tomizawa K, Takemoto T, Mitsudomi T.  Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro.  Lung Cancer  2018    PubMed ID: 30527179
4860  Ishibashi T, Yaguchi A, Terada K, Ueno-Yokohata H, Tomita O, Iijima K, Kobayashi K, Okita H, Fujimura J, Ohki K, Shimizu T, Kiyokawa N.  Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells.  Exp Hematol  2016  44(3):177-88.e5  PubMed ID: 26703895
14149  Shimizu K, Yamasaki S, Shinga J, Sato Y, Watanabe T, Ohara O, Kuzushima K, Yagita H, Komuro Y, Asakura M, Fujii S.  Systemic DC Activation Modulates the Tumor Microenvironment and Shapes the Long-Lived Tumor-Specific Memory Mediated by CD8+ T Cells  Cancer Res  2016  76(13):3756-66  PubMed ID: 27371739
15120  Kobayashi Y, Togashi Y, Yatabe Y, Mizuuchi H, Jangchul P, Kondo C, Shimoji M, Sato K, Suda K, Tomizawa K, Takemoto T, Hida T, Nishio K, Mitsudomi T.  EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs  Clin Cancer Res  2015  21(23):5305-13  PubMed ID: 26206867
8857  Tao Y, Nomura M, Kitabatake N, Tani F.  Mouse CD40-transfected cell lines cannot exhibit the binding and RANTES-stimulating activity of exogenous heat shock protein 70.  Mol. Immunol.  2007  44:1262-73  PubMed ID: 16930707
2559  Shimizu A, Tada K, Shukunami C, Hiraki Y, Kurokawa T, Magane N, Kurokawa-Seo M  A novel alternatively spliced fibroblast growth factor receptor 3 isoform lacking the acid box domain is expressed during chondrogenic differentiation of ATDC5 cells.  J Biol Chem  2001  276:11031-40  PubMed ID: 11134040
2473  Tanaka I, Ishihara H  Enhanced expression of the early retrotransposon in C3H mouse-derived myeloid leukemia cells.  Virology  2001  280:107-14  PubMed ID: 11162824
4871  Feng R, Kabayama A, Uchida K, Hoshino H, Miwa M.  Cell-free entry of human T-cell leukemia virus type 1 to mouse cells.  Jpn J Cancer Res  2001  92(4):410-6  PubMed ID: 11346463
16915  Sun W, Hattori N, Mutai H, Toyoshima Y, Kimura H, Tanaka S, Shiota K.  PAL31, a nuclear protein required for progression to the S phase  Biochem Biophys Res Commun   2001  280(4):1048-54  PubMed ID: 11162633
2951  Yokota S, Kayano T, Ohta T, Kurimoto M, Yanagi H, Yura T, Kubota H  Proteasome-dependent degradation of cytosolic chaperonin CCT  Biochemical and biophysical research communications  2000  279:712-717  PubMed ID: 11118350
2380  Yokota S, Yanagi H, Yura T, Kubota H  Cytosolic chaperonin is up-regulated during cell growth. Preferential expression and binding to tubulin at G(1)/S transition through early S phase.  J Biol Chem  1999  274:37070-8  PubMed ID: 10601265
2215  Saneyoshi K, Nohara O, Imai T, Shiraishi F, Moriyama H, Fujimaki H  IL-4 and IL-6 production of bone marrow-derived mast cells is enhanced by treatment with environmental pollutants.  Int Arch Allergy Immunol  1997  114:237-45  PubMed ID: 9363904
2216  Fujimaki H, Nohara O, Katayama N, Abe T, Nohara K  Ganglioside GM3 inhibits interleukin-3-dependent bone marrow-derived mast cell proliferation.  Int Arch Allergy Immunol  1995  107:527-32  PubMed ID: 7620368
5411  Nakamura M, Sakanaka C, Aoki Y, Ogasawara H, Tsuji T, Kodama H, Matsumoto T, Shimizu T, Noma M.  Identification of two isoforms of mouse neuropeptide Y-Y1 receptor generated by alternative splicing. Isolation, genomic structure, and functional expression of the receptors.  J Biol Chem  1995  270(50):30102-10  PubMed ID: 8530415
1730  Katayama, N., Honda, Y. and Fujimaki, H.  Growth and Functional Modifications in Formaldehyde-Treated Mouse Bone Marrow-Derived Mast Cells  Toxicol in Vitro  1992  6:239-243  PubMed ID: 20732119
1731  Fujimaki H, Kawagoe A, Bissonnette E, Befus D  Mast cell response to formaldehyde. 1. Modulation of mediator release.  Int Arch Allergy Immunol  1992  98:324-31  PubMed ID: 1384864

Back Back Return Top Page